However, combination therapies that include anti-CTLA-4 antibodies and synergistic agents to prime the immune system have significantly enhanced antitumor responses, as shown in the EL4 lymphoma mouse model where coadministration of dendritic cell vaccine and anti-CTLA-4 antibody resulted in tumor responses in 60% of the mice, whereas neither agent alone prevented tumor growth [36]. Here, CTLA4 is linked to neoplasm.